Cite
HARVARD Citation
Hong, X. et al. (2022). Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study. Chinese medical journal. 135 (4), pp. 433-440. [Online].